Please check your internet connection and try again.
# Isoxsuprine Hydrochloride
## Overview
Isoxsuprine hydrochloride is a peripheral vasodilator. Its mechanism of action is not fully understood but is thought to involve direct relaxation of vascular smooth muscle. It also has some beta-adrenergic agonist activity.
## Primary Indications
* Intermittent claudication secondary to peripheral vascular disease. (Note: Its efficacy for this indication is controversial and not widely supported by current evidence.)
## Adult Dosing
* **Intermittent Claudication:** Typically 10-20 mg orally three to four times daily.
## Pediatric Dosing
* No established pediatric dosing.
## Dose Adjustments
* No specific dose adjustments are typically recommended for renal or hepatic impairment, although caution is advised.
## Contraindications
* Use in patients who have had a previous hypersensitivity reaction to isoxsuprine.
* Should not be administered immediately following intravenous infusion of levarterenol.
## Adverse Effects
* **Common:** Hypotension, tachycardia, flushing, dizziness, nausea, vomiting, abdominal distress, weakness, nervousness.
* **Less Common:** Rash, gastrointestinal upset.
## Key Drug Interactions
* **Antihypertensives:** May potentiate the hypotensive effects of antihypertensive medications.
* **Levarterenol (Norepinephrine):** Isoxsuprine may antagonize the pressor effect of levarterenol.
## Monitoring
* Blood pressure and heart rate.
* Signs and symptoms of peripheral vascular disease (e.g., claudication distance, rest pain).
## Clinical Pearls
* The clinical benefit of isoxsuprine for intermittent claudication is not well-established, and its use is limited due to a lack of robust evidence and the availability of more effective treatments.
* Administer with meals to minimize gastrointestinal upset.
* Patients should be advised to report any side effects promptly.
***
**Disclaimer:** This information is intended for healthcare professionals and does not replace comprehensive prescribing information. Always consult the most current drug monograph and institutional protocols for definitive guidance.
